Sorry I disagree. Ive seen this many times. They've run out of shares to short so they are creating by buying options. Mark this post. Short volume will be up again.
fragslap 336 posts | Last Activity: 1 minute 59 seconds ago Member since: Jul 21, 2015
Wow 336 posts in one month! That is an average of 110 posts a day. I hope you get paid by the post. Good luck. Hope you are making a good living.
Itell, nice to see you are active again. This is deja vu for me. When Afreeza got the 2nd CRL about 4 years ago, the price dropped to low $3's, where we are now and you were one of the very few defending the product on this YMB. Nice to see you are defending it again. There's no reason for this price level other than short shares flooding the market and lack of big investors buying in yet. I'm lying low until the 2nd Afreeza launch this September and the 6th month mark for payers to evaluate reimbursement for Afreeza. All in due time.
And it is probably around 130M now with even more shorting this past few days. So do the shorts win since they are holding even more shares now? Ooops. Sorry, if you can't cover, you can't win.
Yes, I heard SNY was contacting you for a clinical trial for a brain tumor drug they are developing. Apparently the FDA approved testing on short bashers on the YMB in lieu of rats.
Don't waste your brain cells trying to make sense of basher logic. We knew when the FDA approved Afrezza that they would have to come up with all sorts of negative slant. Their strategy is to confuse everybody and create chaos. They sometimes look effective simply because they are not bound by any moral or ethical obligations. They've been wrong all along and they will be wrong all the way to oblivion. At the very minimum, there is no need to bash a stock if you don't like it. The drug works and they have no decency to want to see it help anyone.
The data was wrong and completely misleading. They were probably looking at $dollar amounts instead of units. Conceivable the $amounts of Exubera was higher simply because Exubera was too expensive.
dblbgy, the general accounting rule applied is that the milestone payment cannot be booked as revenue until the sale is certain and there is certainty as a "going concern". I suppose the independent accountants need proof that Afreeza will be a success. Does it really matter when they book the revenue? They have the cash on hand. The can call it a "deferred liability" or a Deferred Revenue. People that really know the business know that it's the same thing.
I don't see any 15,000 $17 Jan16 calls. The total outstanding is just 16K. Are you sure you are on the right message board?
Don't forget the diabetes camps happening during the summer. These are were the kids with diabetes go for summer camps. I know that would be off-label use but some kids are 18 or older so its not all off-label. I have a friend attending this type of camp and she will keep me posted if anyone shows up with Afreeza and how it affects others still using their injectibles.
afreezauserchinese, if you have to ask an a message board how to invest on options, I suggest you don't invest on options. Even as an individual expert it is an uphill battle to play against large institutions. Stick to what you know. Biotech is already in the highest risk area of the stock market. Don't quadruple your risk by investing on something you have no idea how it works.
Mattew, I agree with most of what you said, I just don't want to see us hit a huge home run and half the retail investors taken to the cleaners because they "loaned their shares". The banks are not to be trusted. It's always the retail investors that get crushed. I would not be surprised if there is a clause that says you only get the value of the shares at the time of the loan or that in the event the shares cannot be returned, the bank will pay you the original cost of your shares - a guarantee that banks can't lose even if their customers file for bankruptcy.
matthew, I disagree with your statement " we are a drop in the bucket" - we, retail investors are the largest block of investors at 39% (Insiders own 39% and institutional is 22%). However, retail investors are divided and conquered very easily by even the smallest short hedge fund.
We, the retail investors, are the group that kept MNKD afloat in its darkest times.
Trusting these banks that they will make your shares available even when loaned is a big gamble, in my opinion. Are you sure that when this finally pops to $20, $30, or more, that your shares will be returned? Did you read all the fine print? Are you being penny smart and pound foolish?